Syra Health Corp. Class A Common Stock(SYRA)Earnings, Financials & Key Ratios
SYRA•NASDAQ
$0.45
$5M mkt cap·Price updated May 6, 2026
AboutSyra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.Show more
- Revenue$7M-9.5%
- EBITDA-$904K+75.6%
- Net Income-$896K+76.2%
- EPS (Diluted)-0.08+85.5%
- Gross Margin34.43%+66.3%
- EBITDA Margin-12.51%+73.0%
- Operating Margin-12.51%+73.5%
- Net Margin-12.4%+73.7%
- ROE-36.02%+67.0%
- ROIC-86.82%+70.5%
- Debt/Equity0.07-56.4%
- Interest Coverage-68.15+71.8%
SYRA Key Insights
Syra Health Corp. Class A Common Stock (SYRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 99 (top 1%)
- ✓Efficient asset utilization: 2.6x turnover
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 63.1% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SYRA Price & Volume
Syra Health Corp. Class A Common Stock (SYRA) stock price & volume — 10-year historical chart
Loading chart...
SYRA Growth Metrics
Syra Health Corp. Class A Common Stock (SYRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years8.75%
TTM-3.14%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM70.21%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM75.12%
Return on Capital
10 Years-151.47%
5 Years-151.47%
3 Years-87.35%
Last Year-35.02%
SYRA Peer Comparison
Syra Health Corp. Class A Common Stock (SYRA) competitors in Healthcare staffing and facility services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TALK | 869.39M | 5.19 | 129.75 | 22% | 3.4% | 6.89% | ||
 ACMR | 3.67B | 55.38 | 40.42 | 15.24% | 10.44% | 6.11% | 0.16 | |
 CLOV | 1.37B | 2.68 | -15.76 | 40.34% | -2.58% | -17.08% | ||
 LFMD | 252.82M | 5.27 | -22.91 | -8.66% | -7.76% | -162.38% | 0.27 | |
 OPRX | 120.61M | 6.47 | 23.96 | 18.78% | 4.69% | 4.22% | 0.04 | |
 DOCS | 5.17B | 25.69 | 23.14 | 19.98% | 37.54% | 24.45% | 0.01 | |
 HIMS | 6.94B | 26.88 | 52.71 | 59% | 5.47% | 23.73% | 2.07 | |
 TDOC | 1.23B | 6.80 | -5.96 | -1.54% | -6.81% | -12.37% | 0.75 |
Compare SYRA vs Peers
Syra Health Corp. Class A Common Stock (SYRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SYRA Income Statement
Syra Health Corp. Class A Common Stock (SYRA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 1.41M | 5.62M | 5.52M | 7.98M | 7.23M | 7.5M |
| Revenue Growth % | - | - | 298.43% | -1.83% | 44.73% | -9.47% | -3.14% |
| Cost of Goods Sold | 0 | 979.62K | 4.56M | 4.11M | 6.33M | 4.74M | 5.15M |
| COGS % of Revenue | - | 69.48% | 81.1% | 74.46% | 79.29% | 65.57% | - |
| Gross Profit | 0▲ 0% | 430.35K▲ 0% | 1.06M▲ 146.7% | 1.41M▲ 32.7% | 1.65M▲ 17.4% | 2.49M▲ 50.5% | 2.35M▲ 0% |
| Gross Margin % | - | 30.52% | 18.9% | 25.54% | 20.71% | 34.43% | 31.37% |
| Gross Profit Growth % | - | - | 146.72% | 32.66% | 17.35% | 50.5% | - |
| Operating Expenses | 4.27K | 433.63K | 3.15M | 4.3M | 5.42M | 3.39M | 3.62M |
| OpEx % of Revenue | - | 30.75% | 56.1% | 77.96% | 67.88% | 46.94% | - |
| Selling, General & Admin | 4.27K | 416.01K | 3.11M | 4.01M | 1.45M | 1.07M | 3.53M |
| SG&A % of Revenue | - | 29.5% | 55.29% | 72.66% | 18.11% | 14.74% | - |
| Research & Development | 0 | 0 | 0 | 240.05K | 585.15K | 67.84K | 62.58K |
| R&D % of Revenue | - | - | - | 4.35% | 7.33% | 0.94% | - |
| Other Operating Expenses | 0 | 17.63K | 45.59K | 52.14K | 3.39M | 2.26M | 25.45K |
| Operating Income | -4.27K▲ 0% | -3.28K▲ 23.1% | -2.09M▼ 63610.2% | -2.89M▼ 38.2% | -3.76M▼ 30.4% | -904.32K▲ 76.0% | -1.27M▲ 0% |
| Operating Margin % | - | -0.23% | -37.2% | -52.36% | -47.17% | -12.51% | -16.94% |
| Operating Income Growth % | - | 23.13% | -63610.21% | -38.18% | -30.38% | 75.98% | - |
| EBITDA | -4.27K | -3.07K | -2.07M | -2.84M | -3.7M | -904.32K | -1.25M |
| EBITDA Margin % | - | -0.22% | -36.93% | -51.47% | -46.38% | -12.51% | -16.62% |
| EBITDA Growth % | - | 27.98% | -67418.58% | -36.82% | -30.41% | 75.57% | 70.2% |
| D&A (Non-Cash Add-back) | 0 | 207 | 14.85K | 48.77K | 62.74K | 0 | 24.15K |
| EBIT | -4.27K | -3.28K | -2.09M | -2.88M | -3.74M | -904.32K | -1.25M |
| Net Interest Income | 0 | 0 | -28.47K | -50.74K | 5.65K | 7.99K | 4.17K |
| Interest Income | 0 | 0 | 63 | 2.94K | 21.25K | 21.26K | 18.69K |
| Interest Expense | 0 | 0 | 28.53K | 53.69K | 15.6K | 13.27K | 14.52K |
| Other Income/Expense | 0 | 0 | -28.47K | -50.74K | 5.65K | 7.99K | 4.17K |
| Pretax Income | -4.27K▲ 0% | -3.28K▲ 23.1% | -2.12M▼ 64478.2% | -2.94M▼ 38.7% | -3.76M▼ 27.9% | -896.33K▲ 76.2% | -1.27M▲ 0% |
| Pretax Margin % | - | -0.23% | -37.71% | -53.28% | -47.1% | -12.4% | -16.89% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.27K▲ 0% | -3.28K▲ 23.1% | -2.12M▼ 64478.2% | -2.94M▼ 38.7% | -3.76M▼ 27.9% | -896.33K▲ 76.2% | -1.27M▲ 0% |
| Net Margin % | - | -0.23% | -37.71% | -53.28% | -47.1% | -12.4% | -16.89% |
| Net Income Growth % | - | 23.13% | -64478.2% | -38.72% | -27.94% | 76.16% | 70.21% |
| Net Income (Continuing) | -4.27K | -3.28K | -2.12M | -2.94M | -3.76M | -896.33K | -1.27M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00▲ 0% | -0.00▲ 28.6% | -0.29▼ 57900.0% | -0.60▼ 106.9% | -0.52▲ 13.3% | -0.08▲ 85.5% | -0.11▲ 0% |
| EPS Growth % | - | - | - | -106.9% | 13.33% | 85.46% | 75.12% |
| EPS (Basic) | -0.00 | -0.00 | -0.36 | -0.60 | -0.52 | -0.08 | - |
| Diluted Shares Outstanding | 5.98M | 7.28M | 7.28M | 4.88M | 7.26M | 11.85M | 11.94M |
| Basic Shares Outstanding | 5.98M | 7.28M | 5.86M | 4.88M | 7.26M | 11.85M | 11.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
SYRA Balance Sheet
Syra Health Corp. Class A Common Stock (SYRA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 3K | 382.14K | 1.43M | 4.78M | 3.35M | 2.74M | 3.21M |
| Cash & Short-Term Investments | 3K | 100.01K | 3.34K | 3.28M | 2.4M | 1.61M | 1.98M |
| Cash Only | 3K | 100.01K | 3.34K | 3.28M | 2.4M | 1.61M | 1.98M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 282.13K | 1.35M | 1.18M | 680.83K | 918.37K | 926.25K |
| Days Sales Outstanding | - | 73.04 | 87.47 | 78.38 | 31.13 | 46.39 | 41.85 |
| Inventory | 0 | 0 | 47.21K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | 3.78 | - | - | - | - |
| Other Current Assets | 0 | 0 | -17.21K | 0 | 276.56K | 205.42K | 307.79K |
| Total Non-Current Assets | 0 | 154.75K | 892.9K | 142.17K | 325.54K | 34.39K | 52.63K |
| Property, Plant & Equipment | 0 | 154.75K | 296.78K | 142.17K | 325.54K | 34.39K | 52.63K |
| Fixed Asset Turnover | - | 9.11x | 18.93x | 38.79x | 24.52x | 210.14x | 61.19x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 596.12K | 0 | 0 | 0 | 0 |
| Total Assets | 3K▲ 0% | 536.89K▲ 17796.3% | 2.32M▲ 332.1% | 4.92M▲ 112.2% | 3.68M▼ 25.3% | 2.77M▼ 24.6% | 3.26M▲ 0% |
| Asset Turnover | - | 2.63x | 2.42x | 1.12x | 2.17x | 2.61x | 2.12x |
| Asset Growth % | - | 17796.3% | 332.05% | 112.24% | -25.27% | -24.64% | -62.53% |
| Total Current Liabilities | 7.17K | 452.29K | 1.55M | 910.07K | 613.55K | 674.74K | 1.05M |
| Accounts Payable | 0 | 125.73K | 435.59K | 462.99K | 101.69K | 319.52K | 317.41K |
| Days Payables Outstanding | - | 46.85 | 34.9 | 41.15 | 5.86 | 24.61 | 23.07 |
| Short-Term Debt | 3K | 194.2K | 750.55K | 184.9K | 152.89K | 143.79K | 188.9K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 16.61K | 16.61K | 1.02M |
| Other Current Liabilities | -3K | -194.2K | 7.68K | 50.05K | 0 | 194.82K | 137.76K |
| Current Ratio | 0.42x | 0.84x | 0.92x | 5.25x | 5.46x | 4.06x | 4.06x |
| Quick Ratio | 0.42x | 0.84x | 0.89x | 5.25x | 5.46x | 4.06x | 4.06x |
| Cash Conversion Cycle | - | - | 56.35 | - | - | - | 18.78 |
| Total Non-Current Liabilities | 0 | 91.74K | 63.2K | 0 | 187.21K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 187.21K | 0 | 0 |
| Capital Lease Obligations | 0 | 91.74K | 63.2K | 0 | 0 | 0 | 187.21K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 7.17K | 544.04K | 1.61M | 910.07K | 800.76K | 674.74K | 1.05M |
| Total Debt | 3K | 342.86K | 934.84K | 248.1K | 452.08K | 143.79K | 232.35K |
| Net Debt | 0 | 242.85K | 931.5K | -3.03M | -1.94M | -1.47M | -1.74M |
| Debt / Equity | - | - | 1.32x | 0.06x | 0.16x | 0.07x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - | -0.19x |
| Net Debt / EBITDA | - | - | - | - | - | - | 1.40x |
| Interest Coverage | - | - | -73.24x | -53.79x | -241.34x | -68.15x | -86.33x |
| Total Equity | -4.17K▲ 0% | -7.15K▼ 71.5% | 710.1K▲ 10035.6% | 4.01M▲ 465.2% | 2.88M▼ 28.3% | 2.1M▼ 27.1% | 2.21M▲ 0% |
| Equity Growth % | - | -71.51% | 10035.61% | 465.16% | -28.27% | -27.11% | -75.33% |
| Book Value per Share | -0.00 | -0.00 | 0.10 | 0.82 | 0.40 | 0.18 | 0.19 |
| Total Shareholders' Equity | -4.17K | -7.15K | 710.1K | 4.01M | 2.88M | 2.1M | 2.21M |
| Common Stock | 1K | 1K | 4.4K | 6.42K | 9.81K | 12.54K | 12.54K |
| Retained Earnings | -5.17K | -8.45K | -2.13M | -5.06M | -8.82M | -9.72M | -9.59M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SYRA Cash Flow Statement
Syra Health Corp. Class A Common Stock (SYRA) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | 0 | -88.2K | -2.24M | -2.76M | -2.93M | -447.75K | -447.75K |
| Operating CF Margin % | - | -6.26% | -39.95% | -50.03% | -36.73% | -6.2% | - |
| Operating CF Growth % | - | - | -2444.32% | -22.95% | -6.27% | 84.73% | 343.61% |
| Net Income | -51.2K | -3.28K | -2.12M | -2.94M | -3.76M | -896.33K | -1.27M |
| Depreciation & Amortization | 0 | 207 | 14.85K | 48.77K | 62.74K | 20.47K | 24.15K |
| Stock-Based Compensation | 1.2K | 0 | 2.91K | 32.83K | 59.8K | 98.55K | 96.32K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 27.26K | 619.64K | 121.09K | 160.88K | 2.59K | -403.69K |
| Working Capital Changes | 50K | -112.39K | -763.3K | -23.42K | 543.79K | 326.98K | 735.31K |
| Change in Receivables | 0 | -260.63K | -940.47K | -110.16K | 430.42K | -237.55K | -41.81K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 125.73K | 309.86K | 27.4K | -361.3K | 217.83K | 242.25K |
| Cash from Investing | 0 | -6.29K | -121.26K | -15.25K | -11.11K | -107 | 0 |
| Capital Expenditures | 0 | -6.29K | -121.26K | -15.25K | -11.11K | -107 | 0 |
| CapEx % of Revenue | - | 0.45% | 2.16% | 0.28% | 0.14% | 0% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 36K | 191.5K | 2.27M | 6.05M | 2.06M | -332.82K | -347.64K |
| Debt Issued (Net) | 0 | 300 | 736.48K | 518.76K | -410.68K | -347.62K | -362.44K |
| Equity Issued (Net) | 0 | 300 | 1000K | 1000K | 1000K | 14.8K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 36K | 190.9K | -790.32K | 200.01K | 0 | 0 | 14.8K |
| Net Change in Cash | 36K▲ 0% | 97.01K▲ 169.5% | -96.67K▼ 199.6% | 3.28M▲ 3489.7% | -884.67K▼ 127.0% | -780.67K▲ 11.8% | -720.91K▲ 0% |
| Free Cash Flow | 0▲ 0% | -94.49K▲ 0% | -2.37M▼ 2403.3% | -2.77M▼ 17.3% | -2.94M▼ 6.1% | -447.85K▲ 84.8% | -373.28K▲ 0% |
| FCF Margin % | - | -6.7% | -42.1% | -50.3% | -36.87% | -6.2% | -4.98% |
| FCF Growth % | - | - | -2403.31% | -17.29% | -6.09% | 84.78% | 91.68% |
| FCF per Share | - | -0.01 | -0.32 | -0.57 | -0.41 | -0.04 | -0.04 |
| FCF Conversion (FCF/Net Income) | - | 26.89x | 1.06x | 0.94x | 0.78x | 0.50x | 0.29x |
| Interest Paid | 0 | 0 | 0 | 36.23K | 0 | 0 | 8.76K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SYRA Key Ratios
Syra Health Corp. Class A Common Stock (SYRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -602.65% | -124.42% | -109.09% | -36.02% | -50.86% |
| Return on Invested Capital (ROIC) | -2.12% | -166.97% | -165.14% | -294.67% | -86.82% | -86.82% |
| Gross Margin | 30.52% | 18.9% | 25.54% | 20.71% | 34.43% | 31.37% |
| Net Margin | -0.23% | -37.71% | -53.28% | -47.1% | -12.4% | -16.89% |
| Debt / Equity | - | 1.32x | 0.06x | 0.16x | 0.07x | 0.07x |
| Interest Coverage | - | -73.24x | -53.79x | -241.34x | -68.15x | -86.33x |
| FCF Conversion | 26.89x | 1.06x | 0.94x | 0.78x | 0.50x | 0.29x |
| Revenue Growth | - | 298.43% | -1.83% | 44.73% | -9.47% | -3.14% |
SYRA Frequently Asked Questions
Syra Health Corp. Class A Common Stock (SYRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Syra Health Corp. Class A Common Stock (SYRA) reported $7.5M in revenue for fiscal year 2025.
Syra Health Corp. Class A Common Stock (SYRA) saw revenue decline by 9.5% over the past year.
Syra Health Corp. Class A Common Stock (SYRA) reported a net loss of $1.3M for fiscal year 2025.
Dividend & Returns
Syra Health Corp. Class A Common Stock (SYRA) has a return on equity (ROE) of -36.0%. Negative ROE indicates the company is unprofitable.
Syra Health Corp. Class A Common Stock (SYRA) had negative free cash flow of $0.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More SYRA
Syra Health Corp. Class A Common Stock (SYRA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates